|
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[2] ZHENG RS,SUN KX,ZHANG SW,et al. Report of cancer epidemiology in China,2015[J]. Chin J Oncol,2019,41(1):19-28.(in Chinese)郑荣寿，孙可欣，张思维，等．2015年中国恶性肿瘤流行情况分析[J]．中华肿瘤杂志，2019,41(1):19-28.
|
|
[3] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.
|
|
[4] Organ Transplantation Branch,Chinese Medical Doctor Association; Chinese Society of Organ Transplantation,Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma(2018)[J]. J Clin Hepatol,2019,35(2):275-280.(in Chinese)中国医师协会器官移植医师分会，中华医学会器官移植学分会．中国肝癌肝移植临床实践指南(2018版)[J]．临床肝胆病杂志，2019,35(2):275-280.
|
|
[5] China Liver Transplantation Registration Center. China liver transplantation science report 2016[M]. Hangzhou:China Liver Transplantation Registration Center,2017:6.(in Chinese)中国肝移植注册中心．2016中国肝移植科学报告[M]．杭州:中国肝移植注册中心，2017:6.
|
|
[6] MAZZAFERRO V,REGALIA E,DOCI R,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med,1996,334(11):693-699.
|
|
[7] YAO FY,FERRELL L,BASS NM,et al. Liver transplantation for hepatocellular carcinoma:Expansion of the tumor size limits does not adversely impact survival[J]. Hepatology,2001,33(6):1394-1403.
|
|
[8] MAZZAFERRO V,LLOVET JM,MICELI R,et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:A retrospective,exploratory analysis[J]. Lancet Oncol,2009,10(1):35-43.
|
|
[9] FAN J,ZHOU J,XU Y,et al. Indication of liver transplantation for hepatocellular carcinoma:Shanghai Fudan Criteria[J].Natl Med J China,2006,86(18):1227-1231.(in Chinese)樊嘉，周俭，徐泱，等．肝癌肝移植适应证的选择:上海复旦标准[J]．中华医学杂志，2006,86(18):1227-1231.
|
|
[10] ZHENG SS,XU X,WU J,et al. Liver transplantation for hepatocellular carcinoma:Hangzhou experiences[J]. Transplantation,2008,85(12):1726-1732.
|
|
[11] SHEN ZY,DONG C,JIANG WT,et al. Evaluation of criteria in liver transplantation for hepatocellular carcinoma:2393 cases report of liver transplantation for hepatocellular carcinoma[J].Chin J Organ Transplant,2013,34(9):516-520.(in Chinese)沈中阳，董冲，蒋文涛，等．肝细胞癌肝移植适应证标准的评价—2393例临床病例总结[J]．中华器官移植杂志，2013,34(9):516-520.
|
|
[12] TOSO C,MENTHA G,MAJNO P. Liver transplantation for hepatocellular carcinoma:Five steps to prevent recurrence[J]. Am J Transplant,2011,11(10):2031-2035.
|
|
[13] BODZIN AS,LUNSFORD KE,MARKOVIC D,et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation:Impact of treatment modality and recurrence characteristics[J]. Ann Surg,2017,266(1):118-125.
|
|
[14] SAPISOCHIN G,GOLDARACENA N,ASTETE S,et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol,2015,22(7):2286-2294.
|
|
[15] SOTIROPOULOS GC,MOLMENTI EP,LOSCH C,et al. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases[J]. Eur J Med Res,2007,12(10):527-534.
|
|
[16] SOTIROPOULOS GC,LANG H,NADALIN S,et al. Liver transplantation for hepatocellular carcinoma:University Hospital Essen experience and metaanalysis of prognostic factors[J]. J Am Coll Surg,2007,205(5):661-675.
|
|
[17] TOSO C,MEEBERG G,HERNANDEZ-ALEJANDRO R,et al.Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma:A prospective validation[J]. Hepatology,2015,62(1):158-165.
|
|
[18] HAMEED B,MEHTA N,SAPISOCHIN G,et al. Alpha-fetoprotein level> 1000 ng/m L as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria[J]. Liver Transpl,2014,20(8):945-951.
|
|
[19] POTEN,CAUCHY F,ALBUQUERQUE M,et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion[J]. J Hepatol,2015,62(4):848-854.
|
|
[20] SHINDOH J,SUGAWARA Y,NAGATA R,et al. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma[J]. Transpl Int,2014,27(4):391-398.
|
|
[21] FUJIKI M,TAKADA Y,OGURA Y,et al. Significance of desgamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma[J]. Am J Transplant,2009,9(10):2362-2361.
|
|
[22] MILTIADOUS O,SIA D,HOSHIDA Y,et al. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation[J]. J Hepatol,2015,63(6):1368-1377.
|
|
[23] LI MR,CHEN GH,CAI CJ,et al. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence[J]. Digestion,2011,84(2):134-141.
|
|
[24] SAAB S,YEGANEH M,NGUYEN K,et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation[J]. Liver Transpl,2009,15(11):1525-1534.
|
|
[25] REIG M,MARINO Z,PERELLOC,et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J]. J Hepatol,2016,65(4):719-726.
|
|
[26] YANG JD,AQEL BA,PUNGPAPONG S,et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma[J]. J Hepatol,2016,65(4):859-860.
|
|
[27] NAULT JC,COLOMBO M. Hepatocellular carcinoma and direct acting antiviral treatments:Controversy after the revolution[J]. J Hepatol,2016,65(4):663-665.
|
|
[28] ANRS collaborative study group on hepatocellular carcinoma(ANRS CO22 HEPATHER,CO12 Cir Vir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma:Data from three ANRS cohorts[J]. J Hepatol,2016,65(4):734-740.
|
|
[29] HUANG AC,MEHTA N,DODGE JL,et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout[J]. Hepatology,2018,68(2):449-461.
|
|
[30] AN HJ,JANG JW,BAE SH,et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma[J]. Liver Transpl,2012,18(12):1406-1414.
|
|
[31] KORNBERG A,WITT U,KORNBERG J,et al. Postoperative peak serum C-reactive protein is a predictor of outcome following liver transplantation for hepatocellular carcinoma[J].Biomarkers,2016,21(2):152-159.
|
|
[32] HALAZUN KJ,HARDY MA,RANA AA,et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J]. Ann Surg,2009,250(1):141-151.
|
|
[33] AGOPIAN VG,HARLANDER-LOCKE M,ZARRINPAR A,et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation:Analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg,2015,220(4):416-427.
|
|
[34] LAI Q,MELANDRO F,LARGHI LAUREIRO Z,et al. Plateletto-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer:A systematic review and meta-analysis[J]. World J Gastroenterol,2018,24(15):1658-1665.
|
|
[35] ORCI LA,BERNEY T,MAJNO PE,et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. Br J Surg,2015,102(10):1250-1257.
|
|
[36] NAGAI S,YOSHIDA A,FACCIUTO M,et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation[J]. Hepatology,2015,61(3):895-904.
|
|
[37] MAN K,NG KT,LO CM,et al. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastasesactivation of cell invasion and migration pathways[J]. Liver Transpl,2007,13(12):1669-1677.
|
|
[38] HARRIS AL. Hypoxia-a key regulatory factor in tumour growth[J]. Nat Rev Cancer,2002,2(1):38-47.
|
|
[39] ORCI LA,LACOTTE S,OLDANI G,et al. Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis[J]. Br J Surg,2016,103(4):417-426.
|
|
[40] RODRIGUEZ-PERALVAREZ M,de la MATA M,BURROUGHS AK. Liver transplantation:Immunosuppression and oncology[J].Curr Opin Organ Transplant,2014,19(3):253-260.
|
|
[41] RODRIGUEZ-PERALVAREZ M,TSOCHATZIS E,NAVEAS MC,et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol,2013,59(6):1193-1199.
|
|
[42] VILLANUEVA A,CHIANG DY,NEWELL P,et al. Pivotal role of m TOR signaling in hepatocellular carcinoma[J]. Gastroenterology,2008,135(6):1972-1983,1983. e1-11.
|
|
[43] TOSO C,MERANI S,BIGAM DL,et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J]. Hepatology,2010,51(4):1237-1243.
|
|
[44] YANIK EL,CHINNAKOTLA S,GUSTAFSON SK,et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl,2016,22(5):627-634.
|
|
[45] MENON KV,HAKEEM AR,HEATON ND. Meta-analysis:Recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther,2013,37(4):411-419.
|
|
[46] LIANG W,WANG D,LING X,et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma:A meta-analysis[J]. Liver Transpl,2012,18(1):62-69.
|
|
[47] GEISSLER EK,SCHNITZBAUER AA,ZULKE C,et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma:A randomized,multicenter,open-label phase 3 trial[J]. Transplantation,2016,100(1):116-125.
|
|
[48] WEI Q,GAO F,ZHUANG R,et al. A national report from China Liver Transplant Registry:Steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res,2017,29(5):426-437.
|
|
[49] ROAYAIE S,SCHWARTZ JD,SUNG MW,et al. Recurrence of hepatocellular carcinoma after liver transplant:Patterns and prognosis[J]. Liver Transpl,2004,10(4):534-540.
|
|
[50] FENG K,YAN J,LI X,et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol,2012,57(4):794-802.
|
DownLoad: